Rational Advisors LLC acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 6,500 shares of the medical research company’s stock, valued at approximately $769,000.

A number of other large investors have also added to or reduced their stakes in EW. Farmers & Merchants Investments Inc. increased its stake in Edwards Lifesciences Corporation by 9.2% in the first quarter. Farmers & Merchants Investments Inc. now owns 29,326 shares of the medical research company’s stock valued at $2,759,000 after buying an additional 2,480 shares in the last quarter. Howland Capital Management LLC increased its stake in Edwards Lifesciences Corporation by 48.0% in the first quarter. Howland Capital Management LLC now owns 6,987 shares of the medical research company’s stock valued at $657,000 after buying an additional 2,267 shares in the last quarter. Beese Fulmer Investment Management Inc. increased its stake in Edwards Lifesciences Corporation by 9.9% in the first quarter. Beese Fulmer Investment Management Inc. now owns 28,412 shares of the medical research company’s stock valued at $2,672,000 after buying an additional 2,555 shares in the last quarter. Cim LLC acquired a new stake in Edwards Lifesciences Corporation during the first quarter valued at about $7,886,000. Finally, American Research & Management Co. increased its stake in Edwards Lifesciences Corporation by 6.6% in the first quarter. American Research & Management Co. now owns 7,010 shares of the medical research company’s stock valued at $659,000 after buying an additional 435 shares in the last quarter. Institutional investors own 84.15% of the company’s stock.

Shares of Edwards Lifesciences Corporation (EW) opened at 114.50 on Friday. The firm has a market capitalization of $24.18 billion, a PE ratio of 34.73 and a beta of 0.63. The firm’s 50 day moving average is $116.95 and its 200-day moving average is $105.35. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. The company had revenue of $842 million during the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business’s revenue was up 10.9% on a year-over-year basis. During the same period last year, the business earned $0.76 earnings per share. On average, equities research analysts predict that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/13/rational-advisors-llc-invests-769000-in-edwards-lifesciences-corporation-ew.html.

Several equities research analysts have issued reports on the stock. BidaskClub upgraded shares of Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 22nd. Canaccord Genuity restated a “buy” rating and issued a $150.00 target price on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Zacks Investment Research downgraded shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, June 8th. Jefferies Group LLC restated a “buy” rating and issued a $115.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, June 30th. Finally, SunTrust Banks, Inc. upped their target price on shares of Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research note on Monday, July 17th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $121.13.

In other Edwards Lifesciences Corporation news, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $118.05, for a total transaction of $3,883,845.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Patrick B. Verguet sold 22,631 shares of Edwards Lifesciences Corporation stock in a transaction on Friday, May 19th. The shares were sold at an average price of $113.16, for a total value of $2,560,923.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 183,412 shares of company stock valued at $21,176,230. Company insiders own 2.13% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.